AMGN Maintained by RBC Capital -- Price Target Raised to $430
RBC Capital maintained an Outperform rating on Amgen (AMGN) and raised its price target to $430 from $400, citing strong growth potential. Amgen's stock is currently trading at $402.06, which is 9.3% above its GF Value™ of $367.93, indicating overvaluation. The company has a GF Score™ of 85/100, reflecting strong profitability and growth but weaker momentum. Insider activity shows significant selling, with $4.1 million in sales over the past three months.
How this was made
The 30-second read
Why it matters
The higher target may attract buyers, potentially lifting AMGN's price, while insider selling raises caution.
Market read
The analyst's price target increase could influence AMGN trading activity and affect sentiment in the biotech sector.
What to watch
Recent insider selling of $4.1M could temper enthusiasm despite the price target raise.
Background
RBC Capital analyst Luca Issi maintained an Outperform rating on Amgen (AMGN) and raised the price target to $430 from $400, citing growth potential and a strong pipeline.
Ticker impact
RBC Capital raised Amgen's price target to $430 and maintained an Outperform rating.
potential upward pressure as the market prices in the higher target.
RBC cites strong growth prospects and a robust pipeline, increasing the target by 7.5%.
Market effects
Biotech sector may see modest uplift from analyst optimism.
US biotech stocks could experience slight buying pressure.
Impact largely confined to US markets.
Counterpoint
Some investors may view the stock as overvalued given insider selling and high valuation multiples.
Key entities
- CompanyAmgen Inc.
Biotech company whose stock is the subject.
- Analyst FirmRBC Capital
Issued the rating update and price target raise.
